© 2023 MJH Life Sciences and Urology Times. All rights reserved.
© 2023 MJH Life Sciences™ and Urology Times. All rights reserved.
January 27, 2023
Combining the approved antibody-drug conjugates with other agents in this space may provide some synergy and allow even more efficacy and disease control, explains Alicia Morgans, MD.
January 23, 2023
BCAN’s Young Investigator Awards support outstanding early-career scientists and clinical cancer researchers with a demonstrated commitment to improving the understanding and treatment of bladder cancer and/or upper tract urothelial cancer.
"Patients with intermediate-risk NMIBC remain an incredibly heterogeneous group," says Wei Shen Tan, MD, PhD.
January 19, 2023
“I think really identifying who's going to benefit from what combination for how long is going to be important,” says Stephanie Berg, DO.
January 18, 2023
"Our new study is the first post-market analysis to see how doctors are using this drug in routine practice and what their patient outcomes are,” said Soloman Woldu, MD.
Several treatments are being explored across these trials, including pembrolizumab, nivolumab, enfortumab vedotin, durvalumab, avelumab, and cabozantinib.
January 09, 2023
Adding trilaciclib to platinum-based chemotherapy and maintenance avelumab yielded responses in patients with untreated, locally advanced or metastatic urothelial carcinoma.
January 06, 2023
Novel targeted therapy BT8009 granted FDA Fast Track Designation for urothelial cancer.
“Clinicians should do whatever they're able to try to limit or reduce the need for an intraoperative transfusion,” says Timothy D. Lyon, MD, FACS.
January 05, 2023
The acceptance allows investigators to proceed with the phase 1/2a study of the intraoperative immunotherapy SURGERx with resiquimod (STM-416).